Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The safety and efficacy of acalabrutinib for the treatment of R/R MZL

Paolo Strati • 21 Jun 2022
EHA 2022
Lymphoma Marginal Zone Lymphoma Non-Hodgkin Lymphoma Acalabrutinib Antibodies Ibrutinib Rituximab Zanubrutinib

Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the safety and efficacy of acalabrutinib for the treatment of relapsed/refractory marginal zone lymphoma (R/R MZL). Dr Strati first comments on the efficacy of acalabrutinib compared to ibrutinib, and then goes on to discuss the results of a study evaluating the use of acalabrutinib in R/R MZL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Advisory Board/Consultancy: Roche Genentech, Hutchinson MediPharma, ADC Therapeutic, TG Therapeutics, Incyte Morphosis, Kite Gilead
Research Support: Astrazeneca Acerta, ADC Therapeutics, Sobi Pharmaceutics, ALX Oncology

More from Paolo Strati

2:48
BTK inhibitors in the treatment of DLBCL: trials investigating these agents
Paolo Strati • 10 Dec 2023
2:14
Updates on the Smart Stop trial: the potential for a chemo-free regimen in the frontline for DLBCL
Paolo Strati • 10 Dec 2023
1:36
Loncastuximab tesirine as a consolidation strategy post-CAR T-cell therapy in DLBCL
Paolo Strati • 10 Dec 2023
1:55
Autologous SIRPα- low macrophages (SIRPant-M) enhance immune anti-tumor activity in R/R NHL
Paolo Strati • 10 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals